Diffuse mucocutaneous hyperpigmentation related to hydroxyurea Vishnu Sharma, Sidharth Mahajan, Vansh Bagrodia

Can sarcopenia be a risk factor for bleomycin toxicity? M. Koyuncu

Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method Astrid Pavlovsky, Juan Ignacio Garcia Altuve, Amalia Cerutti, Lorena Fiad, Nicolás Kurgansky, Fernando Warley, Florencia Negri Aranguren